Trevi Therapeutics Inc (TRVI) - Net Assets
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has net assets worth $172.13 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($179.61 Million) and total liabilities ($7.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TRVI tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $172.13 Million |
| % of Total Assets | 95.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | 973.17% |
| 10-Year Change | N/A |
| Growth Volatility | 182.8 |
Trevi Therapeutics Inc - Net Assets Trend (2016–2025)
This chart illustrates how Trevi Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See TRVI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual net assets of Trevi Therapeutics Inc from 2016 to 2025. For live valuation and market cap data, see how much is Trevi Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $183.24 Million | +83.90% |
| 2024-12-31 | $99.64 Million | +20.71% |
| 2023-12-31 | $82.55 Million | -23.18% |
| 2022-12-31 | $107.46 Million | +529.34% |
| 2021-12-31 | $17.07 Million | -37.41% |
| 2020-12-31 | $27.28 Million | -49.98% |
| 2019-12-31 | $54.55 Million | +215.16% |
| 2018-12-31 | $17.31 Million | +17.11% |
| 2017-12-31 | $14.78 Million | +184.88% |
| 2016-12-31 | $-17.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Trevi Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25764700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $128.00K | 0.07% |
| Other Comprehensive Income | $148.00K | 0.08% |
| Other Components | $512.77 Million | 279.83% |
| Total Equity | $183.24 Million | 100.00% |
Trevi Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Trevi Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Hope Dairy Co Ltd
SHE:002946
|
$1.89 Billion |
|
Nancal Energy-Saving Tech Co
SHG:603859
|
$1.89 Billion |
|
Qingdao Yunlu Advanced Materials Technology Co. Ltd. A
SHG:688190
|
$1.90 Billion |
|
Ningbo Kangqiang Electronics Co Ltd
SHE:002119
|
$1.90 Billion |
|
Terravest Capital Inc
TO:TVK
|
$1.89 Billion |
|
Sinofibers Technology Co Ltd
SHE:300777
|
$1.89 Billion |
|
Sunway Real Estate Investment Trust
KLSE:5176
|
$1.89 Billion |
|
Homeco Daily Needs REIT
AU:HDN
|
$1.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Trevi Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 99,644,000 to 183,244,000, a change of 83,600,000 (83.9%).
- Net loss of 42,759,000 reduced equity.
- New share issuances of 108,154,000 increased equity.
- Other comprehensive income increased equity by 87,000.
- Other factors increased equity by 18,118,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-42.76 Million | -23.33% |
| Share Issuances | $108.15 Million | +59.02% |
| Other Comprehensive Income | $87.00K | +0.05% |
| Other Changes | $18.12 Million | +9.89% |
| Total Change | $- | 83.90% |
Book Value vs Market Value Analysis
This analysis compares Trevi Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.08 | $17.21 | x |
| 2017-12-31 | $1.65 | $17.21 | x |
| 2018-12-31 | $1.93 | $17.21 | x |
| 2019-12-31 | $3.06 | $17.21 | x |
| 2020-12-31 | $1.51 | $17.21 | x |
| 2021-12-31 | $0.75 | $17.21 | x |
| 2022-12-31 | $1.66 | $17.21 | x |
| 2023-12-31 | $0.83 | $17.21 | x |
| 2024-12-31 | $0.99 | $17.21 | x |
| 2025-12-31 | $1.26 | $17.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Trevi Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-23.33%) is above the historical average (-70.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.35 Million |
| 2017 | -87.02% | 0.00% | 0.00x | 1.50x | $-14.34 Million |
| 2018 | -118.71% | 0.00% | 0.00x | 1.18x | $-22.28 Million |
| 2019 | -47.76% | 0.00% | 0.00x | 1.10x | $-31.50 Million |
| 2020 | -120.07% | 0.00% | 0.00x | 1.73x | $-35.49 Million |
| 2021 | -198.77% | 0.00% | 0.00x | 2.25x | $-35.65 Million |
| 2022 | -27.13% | 0.00% | 0.00x | 1.14x | $-39.90 Million |
| 2023 | -35.21% | 0.00% | 0.00x | 1.08x | $-37.32 Million |
| 2024 | -48.08% | 0.00% | 0.00x | 1.11x | $-57.88 Million |
| 2025 | -23.33% | 0.00% | 0.00x | 1.06x | $-61.08 Million |
Industry Comparison
This section compares Trevi Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Trevi Therapeutics Inc (TRVI) | $172.13 Million | 0.00% | 0.04x | $1.89 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more